Weight regain after completion of SURMOUNT-CN trial: The SURMOUNT-CN trial follow-up study (SURMOUNT-CN follow-up study)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/105087
• EU PAS number:
  EUPAS103493
• Study ID:
  105087
• Official title and acronym:
  Weight regain after completion of SURMOUNT-CN trial: The SURMOUNT-CN trial follow-up study (SURMOUNT-CN follow-up study)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  This is a real-world observational study with primary data collection and secondary data use. This follow-up study will enroll patients who completed the SURMOUNT-CN trial, with a planned follow-up duration of 26 weeks. The aim of this follow-up study is to examine changes in body weight and waist circumferences in 26 weeks at 13-weekly intervals from treatment cessation among those who completed SURMOUNT-CN trial in real-world practice settings in China. No investigational medicine is applied in this follow-up study. The follow-up data will be provided by patients, whereas study baseline data (at trial randomization, week 52 and week 56) will be derived from SURMOUNT-CN trial via patient-level data linkage.
• Study status:
  Ongoing

Research institutions and networks

Institutions

ZhongShan Hospital

Study timelines

Date when funding contract was signed

Actual: 27/10/2022

Study start date

Planned: 28/04/2023

Actual: 19/04/2023

Date of final study report

Planned: 29/12/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

Pangaea number:2022-11868